Iopidine (Apraclonidine Hydrochloride)

Apraclonidine selectively stimulates alpha‑2 adrenergic receptors in the ciliary body, which reduces the production of aqueous humor and enhances uveoscleral outflow, leading to a decrease in intra‑ocular pressure.

The dosing regimen for Iopidine is determined by the prescribing eye‑care professional based on the patient’s condition, response, and tolerance. The prescriber will specify the number of drops and frequency.

Safety data for apraclonidine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Iopidine, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iopidine (apraclonidine) is an alpha‑2 agonist, whereas many other glaucoma drops are beta‑blockers, prostaglandin analogues or carbonic anhydrase inhibitors. Apraclonidine primarily reduces aqueous humor production and can be used as adjunct therapy when other agents alone are insufficient.

Iopidine should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed in its original packaging until use.

Iopidine is applied as eye drops. The patient instills the prescribed number of drops into the affected eye(s) as directed by the ophthalmologist, typically avoiding contact with the eyelid or lashes.

Serious risks include allergic reactions such as contact dermatitis, severe eye pain or corneal edema, and systemic effects like hypotension or bradycardia, especially when used with other alpha‑2 agonists or antihypertensive drugs.

Patients with known hypersensitivity to apraclonidine or any component of the formulation should avoid Iopidine. Caution is also advised for individuals with severe cardiovascular disease, uncontrolled hypotension, or those taking systemic alpha‑2 agonists.